Display options
Share it on
Full text links
HighWire Free PMC Article

Heart. 1998 Oct;80(4):334-7. doi: 10.1136/hrt.80.4.334.

von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.

Heart (British Cardiac Society)

J H Jansson, O Johnson, T K Nilsson

Affiliations

  1. Department of Internal Medicine, Skellefteå Hospital, Sweden.

PMID: 9875107 PMCID: PMC1728802 DOI: 10.1136/hrt.80.4.334
Free PMC Article

Abstract

BACKGROUND: Haemostasis plays a major part in the process initiating a myocardial infarction. The impact of haemostatic variables on long term prognosis is unknown.

OBJECTIVE: To evaluate von Willebrand factor (vWF), tissue plasminogen activator antigen (t-PA) and its activity before and after venous occlusion, plasminogen activator inhibitor (PAI-1), dehydroepian-drosterone sulphate (DHEAS), and established clinical risk factors as long term predictors for reinfarction and mortality.

PATIENTS: 123 consecutive survivors of myocardial infarction followed up for 10 years.

DESIGN: Study entry took place between 1982 and 1983. Fifty seven patients died (54 of cardiovascular disease) during the mean observation time of 10 years.

RESULTS: Cox's univariate regression analysis showed that cardiovascular mortality was significantly associated with age, hypertension, previous history of angina pectoris, DHEAS, mass concentration of t-PA, and vWF. These associations were significant for vWF and mass concentration of t-PA after adjusting for age and hypertension.

CONCLUSIONS: A low concentration of DHEAS and high levels of the endothelially derived haemostatic variables vWF and mass concentration of t-PA are predictors of cardiovascular mortality in survivors of myocardial infarction. This association is independent of established clinical risk factors for mass concentration of t-PA and vWF.

Cited by

Zhai G, Teumer A, Stolk L, Perry JR, Vandenput L, Coviello AD, Koster A, Bell JT, Bhasin S, Eriksson J, Eriksson A, Ernst F, Ferrucci L, Frayling TM, Glass D, Grundberg E, Haring R, Hedman AK, Hofman A, Kiel DP, Kroemer HK, Liu Y, Lunetta KL, Maggio M, Lorentzon M, Mangino M, Melzer D, Miljkovic I, Nica A, Penninx BW, Vasan RS, Rivadeneira F, Small KS, Soranzo N, Uitterlinden AG, Völzke H, Wilson SG, Xi L, Zhuang WV, Harris TB, Murabito JM, Ohlsson C, Murray A, de Jong FH, Spector TD, Wallaschofski H.
PLoS Genet. 2011 Apr;7(4):e1002025. doi: 10.1371/journal.pgen.1002025. Epub 2011 Apr 14.
PMID: 21533175

References

  1. Proc Soc Exp Biol Med. 1967 Aug-Sep;125(4):1136-40 - PubMed
  2. Thromb Haemost. 1995 Aug;74(2):612-5 - PubMed
  3. Diabetes. 1982 Sep;31(9):830-3 - PubMed
  4. Thromb Haemost. 1983 Dec 30;50(4):800-3 - PubMed
  5. Thromb Haemost. 1984 Oct 31;52(2):127-30 - PubMed
  6. N Engl J Med. 1985 Dec 19;313(25):1557-63 - PubMed
  7. Acta Chir Scand. 1985;151(6):515-9 - PubMed
  8. Lancet. 1986 Sep 6;2(8506):533-7 - PubMed
  9. N Engl J Med. 1986 Dec 11;315(24):1519-24 - PubMed
  10. Lancet. 1987 Jul 4;2(8549):3-9 - PubMed
  11. Thromb Res. 1987 Dec 15;48(6):621-30 - PubMed
  12. Atherosclerosis. 1989 Oct;79(2-3):197-203 - PubMed
  13. J Am Coll Cardiol. 1990 Nov;16(6):862-70 - PubMed
  14. J Androl. 1990 Sep-Oct;11(5):460-70 - PubMed
  15. Eur Heart J. 1991 Feb;12(2):157-61 - PubMed
  16. Mayo Clin Proc. 1991 Jun;66(6):634-40 - PubMed
  17. Br Heart J. 1991 Nov;66(5):351-5 - PubMed
  18. Arterioscler Thromb. 1992 Sep;12(9):1063-70 - PubMed
  19. Circulation. 1992 Nov;86(5):1529-35 - PubMed
  20. Lancet. 1993 May 8;341(8854):1165-8 - PubMed
  21. Lancet. 1993 Oct 30;342(8879):1076-9 - PubMed
  22. Circulation. 1994 Jan;89(1):89-93 - PubMed
  23. N Engl J Med. 1995 Mar 9;332(10):635-41 - PubMed
  24. Acta Med Scand. 1976;200(3):223-8 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources